Concepedia

Scott Mix

SM

Statistics

Publications

1

Citations

30

H-Index

1

Active since

2022

Affiliations

Bexon Clinical Consulting (United States)(Current)

Scott Mix is an author at Bexon Clinical Consulting (United States) specializing in toll-like receptor antagonism, pharmacodynamics of immunotherapies, and innate immunity.

ORCID

Publications per year

2022–2022

1

Publications

1

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation

Weston L. Daniel, Ulrike Lorch, Scott Mix et al. · Frontiers in Immunology · 2022 · 30 citations · Full text

Life Sciences, Immunology, Pharmacology +13

1–1 of 1